MMP2 and breast carcinoma: Breast cancer cells treated with dasatinib showed a decrease of pSRC(Tyr416) expression (Fig. 2a and Additional file 1: Figure S1E); moreover, this treatment led to a decrease in cell migration (Fig. 2b) and cell invasion (Fig. 2c), associated with a decrease of MMP2 activity and sP-cad expression in the conditioned media (Fig. 2d), as well as with a decreased mammosphere forming efficiency (MFE) (Fig. 2e).